Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Med Chem ; 17(8): 834-843, 2021.
Article in English | MEDLINE | ID: mdl-32520690

ABSTRACT

BACKGROUND: One of the best methods to treat Alzheimer disease (AD) is through the effective use of cholinesterase inhibitors as vital drugs due to the identification of acetylcholine deficit in the AD patients. OBJECTIVE: The present study aims the investigation of spiro heterocyclic compounds as potential AD agents supported by their metal chelation capacity, POM analyses and DFT studies, respectively. METHODS: The cholinesterase inhibition and metal chelation ability were performed on ELISA microtiter assay. Whereas, the B3LYP method with 6-31+G(d,p) basis set was implemented to study HOMOLUMO energy calculations. The pharmacokinetic properties of the synthesized molecules were studied through Petra, Osiris and Molinspiration (POM). RESULTS: The six spiro (1-6) skeletons were tested for their inhibitory potential and metal-chelation capacity. Our findings revealed that the tested spiro skeletons exerted none or lower than 50% inhibition against both cholinesterases, while compound 4 proved to be the most active molecule with 57.21±0.89% of inhibition toward BChE. The spiro molecule 3 exhibited the highest metal-chelation capacity (9.12±5.26%). Molecular docking model for the most active molecule exhibited promising bindings with AChE and BChE's active site pertained to hydrophobic hydrogen bonds and positive ionizable interactions. The POM analyses gave the information about the flexibility at the site of coordination of spiro compounds (1-6). CONCLUSION: The screening of spirocompounds (1-6) against cholinesterases revealed that some of them show considerable potential to inhibit AChE and BChE. Herein, we propose that the spiro molecules after further derivatization could serve interesting AD inhibitor drugs.


Subject(s)
Alzheimer Disease/drug therapy , Chelating Agents/chemistry , Chelating Agents/pharmacology , Heterocyclic Compounds/chemistry , Spiro Compounds/chemistry , Spiro Compounds/pharmacology , Molecular Conformation , Molecular Docking Simulation , Spiro Compounds/therapeutic use , Structure-Activity Relationship
2.
Molecules ; 22(6)2017 Jun 11.
Article in English | MEDLINE | ID: mdl-28604614

ABSTRACT

Diazocoupling reaction of curcumin with different diazonium salts of p-toluidine, 2-aminopyridine, and 4-aminoantipyrine in pyridine yielded the arylhydrazones 2a-c. Arylhydrazone of p-toluidine reacted with urea, thiourea, and guanidine nitrate to produce 5,6-dihydropyrimidines. Further reaction of 2a with 2,3-diaminopyrdine in sodium ethoxide solution yielded 1H-pyrido[2,3-b][1,4]diazepine derivative. Bis(2,5-dihydroisoxazole) is obtained from the reaction of 2a with hydroxylamine hydrochloride, while its reactions with hydrazines afforded the respective 4,5-dihydro-1H-pyrazoles. The target compounds were evaluated as antioxidant and antibacterial agents. The tested compounds showed good to moderate activities compared to ascorbic acid and chloramphenicol, respectively.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antioxidants/pharmacology , Curcumin/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Aminopyridines/chemical synthesis , Aminopyridines/chemistry , Ampyrone/chemical synthesis , Ampyrone/chemistry , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Antioxidants/chemical synthesis , Antioxidants/chemistry , Ascorbic Acid/pharmacology , Chloramphenicol/pharmacology , Curcumin/analogs & derivatives , Curcumin/chemical synthesis , Curcumin/chemistry , Diazonium Compounds/chemical synthesis , Diazonium Compounds/chemistry , Gram-Negative Bacteria/pathogenicity , Gram-Positive Bacteria/pathogenicity , Humans , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity Relationship , Toluidines/chemical synthesis , Toluidines/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...